Integra LifeSciences Swings To Earnings In Q3; Guides Q4, FY26
Integra LifeSciences (IART) reported Q3 net income of $14.85M, up from a $5.40M loss last year. Revenue rose to $411.18M. The company guided Q4 revenue between $413M-$433M and FY26 revenue between $1.634B-$1.654B. Adjusted EPS for Q4 is expected to be $0.61-$0.71, and $2.30-$2.40 for FY26.
How this was made
The 30-second read
Why it matters
The earnings beat may provide short‑term support, but the guidance indicating a revenue contraction could lead to a pullback. Traders should watch volume and any forward‑looking commentary from management.
Market read
Primary earnings release with fresh guidance; directly influences IART price and may affect peer med‑tech stocks.
What to watch
Potential upside from upcoming product launches or contract wins not disclosed in this release.
Background
Integra LifeSciences is a medical device and specialty surgical company listed on Nasdaq. The Q3 results mark a turnaround from a loss year‑over‑year.
Ticker impact
Integra LifeSciences reported Q3 profit and issued Q4 revenue guidance that shows a slight decline, providing fresh earnings data and guidance.
modest downside pressure as investors price in lower Q4 revenue guidance
The earnings beat is offset by guidance that projects a revenue decline of up to 5.2%, which may trigger short‑term selling.
Market effects
Medical device sector may see slight pressure as guidance hints at slower growth, but overall sector remains stable.
U.S. market impact limited to healthcare stocks; no broader regional effect.
Minimal global relevance beyond investors tracking U.S. med‑tech equities.
Counterpoint
Despite the revenue dip, the profit swing and strong adjusted EBITDA could support a bounce if the market overreacts.
Key entities
- companyIntegra LifeSciences Holdings Corp.
U.S.-listed medical device company reporting Q3 earnings and Q4 guidance.
